Trifluridine
Antivirals
Sold as LONSURF · VIROPTIC
- Drug class
- Antivirals
- Availability
- See label
- Routes
- Ophthalmic, Oral
- Markets covered
- 3
- Products on record
- 5
Overview
Trifluridine is an active pharmaceutical ingredient in the Antivirals group (S01AD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 3 | March 22, 2025 |
| GB United Kingdom | MHRA | 1 | May 1, 2026 |
| EU European Union | EMA | 1 | April 5, 2024 |
CACanada· Health Canada
3 products
Uses
Lonsurf® (trifluridine and tipiracil [as tipiracil hydrochloride] tablets) is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.
Lonsurf monotherapy is indicated for the treatment of adult patients with metastatic gastric cancer or adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior lines of chemotherapy including a fluoropyrimidine, a platinum, and either a taxane or irinotecan and if appropriate with HER2/neu-targeted therapy.
Clinical effectiveness of Lonsurf is based on benefit observed in a pivotal study in patients who had been previously treated with all of the above available therapies. 1 Pediatrics Pediatrics (0 – 18 years): No pediatric data have been made available to Health Canada; therefore, Health Canada has not approved an indication for pediatric use.
GBUnited Kingdom· MHRA
1 product
Uses
Colorectal cancer Trifluridine/ Tipiracil is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti- EGFR agents.
Trifluridine/ Tipiracil is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
1).
How to take
EUEuropean Union· EMA
1 product
Uses
Colorectal cancer Lonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
1). 3
How to take
Drug interactions
Known interactions involving Trifluridine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02472104 · revised March 22, 2025
- [2]MHRA (UK) · PLGB058150112 · revised May 1, 2026
- [3]European Medicines Agency · EMEA/H/C/003897 · revised April 5, 2024
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.